(Reuters) – The United States will announce on Tuesday that it has signed a $354 million contract with a company to make generic medicines and pharmaceutical ingredients in the country needed to treat COVID-19, the New York Times reported late on Monday.
The move is part of efforts to bring pharmaceutical manufacturing to the United States from abroad. Phlow Corp is a generic drug maker based in Virginia which makes medicines overseas, mostly in India and China.